INTERFERON AND B-CELL PROLYMPHOCYTIC LEUKAEMIA
نویسندگان
چکیده
منابع مشابه
T-Cell Prolymphocytic Leukaemia: A Case Series
T-prolymphocytic leukaemia (T-PLL) is a rare mature T-cell lymphoproliferative disorder. It is seen more often in middle-aged and elderly individuals with a median age of onset of 65 years and a male predominance of 2:1. Patients present with hepatosplenomegaly, lymphadenopathy, 15% may have serous effusions and approximately 20% have skin involvement. The white cell count is often above 200 x ...
متن کاملBendamustine is effective in T-cell prolymphocytic leukaemia.
T-cell prolymphocytic leukaemia (T-PLL) is an aggressive T-cell neoplasm with a mature post-thymic T-cell phenotype. Most patients present with markedly elevated leucocyte counts, splenomegaly, lymphadenopathy, hepatomegaly, skin lesions, pleuroperitoneal effusions or central nervous system involvement (Matutes et al, 1991). The most frequent chromosome abnormalities in T-PLL are inv(14)(q11q32...
متن کاملp53 abnormalities in B-cell prolymphocytic leukemia.
B-cell prolymphocytic leukemia (B-PLL) is an aggressive disorder of mature B cells with distinct clinical and pathologic features. To determine the incidence of abnormalities of p53, we analyzed 19 cases of B-PLL by DNA blot to assess loss of heterozygosity (LOH) at 17p13.3, by immunocytochemistry to assess p53 expression, and by direct DNA sequencing of polymerase chain reaction-amplified exon...
متن کاملIntracytoplasmic inclusions in B prolymphocytic leukaemia: ultrastructural, cytochemical, and immunological studies.
The intracytoplasmic inclusions seen in most cells from a patient with B prolymphocytic leukaemia were analysed using both light and electron microscopy. They consisted of a dense homogeneous structure and were surrounded by a membrane, which had no continuity with the Golgi cisternae or the endoplasmic reticulum; some inclusions had a clear association with small lysosomal granules. Immunofluo...
متن کاملB- and T-cell prolymphocytic leukemia: antibody approaches.
B- and T-cell subtypes of prolymphocytic leukemia (PLL) are rare, aggressive lymphoid malignancies with characteristic morphologic, immunophenotypic, cytogenetic, and molecular features. Prognosis for these patients remains poor, with short survival times and no curative therapy. The advent of mAbs has improved treatment options. In B-PLL, rituximab-based combination chemoimmunotherapy is effec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 1987
ISSN: 0007-1048,1365-2141
DOI: 10.1111/j.1365-2141.1987.tb01347.x